Adding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival time for patients with advanced biliary tract cancers, but it may provide a benefit for subsets of patients with locally-advanced disease or gallbladder adenocarcinoma.
In a pilot study, a telephone-based dietary intervention designed to improve bowel function was shown to be widely acceptable to participants who had had surgery for rectal cancer.
